{"title":"arfa射频消融系统Ⓡ在多器官经皮射频消融的临床经验。","authors":"Naoya Kinota, Haruyuki Takaki, Kaoru Kobayashi, Yasukazu Kako, Hiroshi Kodama, Atsushi Ogasawara, Mitsunari Maruyama, Motonori Takahagi, Junichi Taniguchi, Taiki Moriyama, Hiroyuki Yokoyama, Hisashi Komoto, Ryo Kunimoto, Nahomi Yoshimura, Koichiro Yamakado","doi":"10.22575/interventionalradiology.2022-0012","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the feasibility, safety, and efficacy of radiofrequency (RF) ablation using an ablation system (arfa RF ABLATION SYSTEM<sup>Ⓡ</sup>; Japan Lifeline Co. Ltd.) for treating solid tumors in various organs.</p><p><strong>Material and methods: </strong>Between October 2019 and August 2021, 80 patients (29 women, 51 men; median age, 70.0 yr) underwent 107 RF ablation sessions using the ablation system to treat 151 tumors in the liver (<i>n =</i> 86), lung (<i>n =</i> 51), adrenal gland (<i>n =</i> 4), pleura (<i>n =</i> 4), bone (<i>n =</i> 3), lymph node (<i>n =</i> 2), and kidney (<i>n =</i> 1). The maximum tumor diameter was 2-40 mm (median, 11 mm). This study evaluated technical success (defined as the completion of planned RF ablation), technique efficacy (defined as the complete tumor ablation on follow-up images), and adverse events. Local tumor progression in 146 curatively treated malignant tumors was evaluated.</p><p><strong>Results: </strong>The technical success rate was 100% (107/107). Ablation zones in two tumors were insufficient. Therefore, the primary technique efficacy rate was 98.1% (105/107). Grade 3 hepatic infarction (1.6%, 1/64) and grade 4 pleuritis (3.4%, 1/29) occurred respectively after liver and lung RF ablation. During the median follow-up period of 10.2 months (Interquartile range, 4.2 and 16.4 months), local tumor progression developed in two tumors (1.4%, 2/146).</p><p><strong>Conclusions: </strong>The arfa RF ABLATION SYSTEM<sup>Ⓡ</sup> is a feasible, safe, and effective RF ablation device for managing solid tumors in various organs.</p>","PeriodicalId":73503,"journal":{"name":"Interventional radiology (Higashimatsuyama-shi (Japan)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/5b/2432-0935-7-3-0093.PMC9719816.pdf","citationCount":"0","resultStr":"{\"title\":\"Clinical Experience of Percutaneous Radiofrequency Ablation Using an arfa RF ABLATION SYSTEM<sup>Ⓡ</sup> in Various Organs.\",\"authors\":\"Naoya Kinota, Haruyuki Takaki, Kaoru Kobayashi, Yasukazu Kako, Hiroshi Kodama, Atsushi Ogasawara, Mitsunari Maruyama, Motonori Takahagi, Junichi Taniguchi, Taiki Moriyama, Hiroyuki Yokoyama, Hisashi Komoto, Ryo Kunimoto, Nahomi Yoshimura, Koichiro Yamakado\",\"doi\":\"10.22575/interventionalradiology.2022-0012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the feasibility, safety, and efficacy of radiofrequency (RF) ablation using an ablation system (arfa RF ABLATION SYSTEM<sup>Ⓡ</sup>; Japan Lifeline Co. Ltd.) for treating solid tumors in various organs.</p><p><strong>Material and methods: </strong>Between October 2019 and August 2021, 80 patients (29 women, 51 men; median age, 70.0 yr) underwent 107 RF ablation sessions using the ablation system to treat 151 tumors in the liver (<i>n =</i> 86), lung (<i>n =</i> 51), adrenal gland (<i>n =</i> 4), pleura (<i>n =</i> 4), bone (<i>n =</i> 3), lymph node (<i>n =</i> 2), and kidney (<i>n =</i> 1). The maximum tumor diameter was 2-40 mm (median, 11 mm). This study evaluated technical success (defined as the completion of planned RF ablation), technique efficacy (defined as the complete tumor ablation on follow-up images), and adverse events. Local tumor progression in 146 curatively treated malignant tumors was evaluated.</p><p><strong>Results: </strong>The technical success rate was 100% (107/107). Ablation zones in two tumors were insufficient. Therefore, the primary technique efficacy rate was 98.1% (105/107). Grade 3 hepatic infarction (1.6%, 1/64) and grade 4 pleuritis (3.4%, 1/29) occurred respectively after liver and lung RF ablation. During the median follow-up period of 10.2 months (Interquartile range, 4.2 and 16.4 months), local tumor progression developed in two tumors (1.4%, 2/146).</p><p><strong>Conclusions: </strong>The arfa RF ABLATION SYSTEM<sup>Ⓡ</sup> is a feasible, safe, and effective RF ablation device for managing solid tumors in various organs.</p>\",\"PeriodicalId\":73503,\"journal\":{\"name\":\"Interventional radiology (Higashimatsuyama-shi (Japan)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/5b/2432-0935-7-3-0093.PMC9719816.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Interventional radiology (Higashimatsuyama-shi (Japan)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22575/interventionalradiology.2022-0012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interventional radiology (Higashimatsuyama-shi (Japan)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22575/interventionalradiology.2022-0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical Experience of Percutaneous Radiofrequency Ablation Using an arfa RF ABLATION SYSTEMⓇ in Various Organs.
Purpose: To evaluate the feasibility, safety, and efficacy of radiofrequency (RF) ablation using an ablation system (arfa RF ABLATION SYSTEMⓇ; Japan Lifeline Co. Ltd.) for treating solid tumors in various organs.
Material and methods: Between October 2019 and August 2021, 80 patients (29 women, 51 men; median age, 70.0 yr) underwent 107 RF ablation sessions using the ablation system to treat 151 tumors in the liver (n = 86), lung (n = 51), adrenal gland (n = 4), pleura (n = 4), bone (n = 3), lymph node (n = 2), and kidney (n = 1). The maximum tumor diameter was 2-40 mm (median, 11 mm). This study evaluated technical success (defined as the completion of planned RF ablation), technique efficacy (defined as the complete tumor ablation on follow-up images), and adverse events. Local tumor progression in 146 curatively treated malignant tumors was evaluated.
Results: The technical success rate was 100% (107/107). Ablation zones in two tumors were insufficient. Therefore, the primary technique efficacy rate was 98.1% (105/107). Grade 3 hepatic infarction (1.6%, 1/64) and grade 4 pleuritis (3.4%, 1/29) occurred respectively after liver and lung RF ablation. During the median follow-up period of 10.2 months (Interquartile range, 4.2 and 16.4 months), local tumor progression developed in two tumors (1.4%, 2/146).
Conclusions: The arfa RF ABLATION SYSTEMⓇ is a feasible, safe, and effective RF ablation device for managing solid tumors in various organs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
